The PHARM Connect Congress 2011

9-10 February 2011, Budapest, Hungary.
The PHARM Connect Congress 2011, an event organised by The Events Group, offers the perfect setting for solution providers to present their products and services directly to key decision makers of target client population throughout Central & Eastern Europe.

Strictly operating on an invitation only basis guarantees that the highest level of delegation is present. Each solution provider at the PHARM Connect Congress is selected based on requirements and interests provided by attending Pharmaceutical professionals prior to the Congress event.

Over two days, service providers will meet and interact with the leading director and C level practitioners through a number of pre-arranged one-to-one business meetings and other networking activities.

Several weeks in advance of the Congress, the TEG Meeting Scheduler is made available to all solution providers and delegates attending. Participants receive individualized passwords to access the website where they are able to select key presentations, pre-schedule one-to-one meetings and confirm their presence at several additional networking activities. Through the Meeting Scheduler, attendees have the opportunity to create their own itinerary prior to the Congress taking place.

This networking event presents a unique opportunity to develop meaningful and valuable business relations.

For further information and registration, please visit:
http://www.pharmconnect.eu

About The Events Group
The Events Group is one of Europe's leading business information providers. With two main areas of focus, business-to-business Congresses and Professional Training, we primarily operate within key emerging markets: Central & Eastern Europe.

Our unique business-to-business Congresses bring together senior-level executives from Europe’s largest organisations with a select and diversified group of leading edge sponsors. Strictly operating on an invitation only basis guarantees that the highest level of delegation is present.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

A great place to do great things: Developing game-…

Science has spoken: Abbott (NYSE: ABT) is, again, among the best science-based companies to work for in the world. For the 14th year, the journal Science today recognized...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Scientists find where HIV 'hides' to evade detecti…

In a decades-long game of hide and seek, scientists from Sydney's Westmead Institute for Medical Research have confirmed for the very first time the specific immune memor...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]